Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | UNK | — | OT |
Posttransplant HBV vaccine completion with HBsAb testing. HBsAb < 10 IU/L. = 5 (71); This literature marketed report has been received from the authors of the published article and refers to a 53-year-old female adult patient. The patient's medical history included lung transplantation with no acute rejection. The patient's concurrent conditions were not reported. Concomitant therapies included alemtuzumab (induction). On an unknown date, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) 40 mcg/mL, 3 dosage regimen (0, 1, 6 months) (RECOMBIVAX HB) (route of administration, vaccination site, vaccination scheme, lot #, and expiration date were not reported) as a prophylaxis. On an unknown date (Posttransplant HBV vaccine completion), the hepatitis B surface antigen (HBsAb) testing was minor to 10 IU/L (vaccination failure). At the reporting time, the outcome of was unknown. The reporter considered the event of vaccination failure to be related to Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB). This is one case of several received from the same literature article. Lot # is being requested and will be submitted if received.
Medical History/Concurrent Conditions: Lung transplant
Test Name: HBsAb; Result Unstructured Data: Minor to 10 IU/L